Science

Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors – The Babak Lab

The Babak Lab/LinkedIn

Mar 22, 2025, 07:56

Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors – The Babak Lab

The Babak Lab shared an article by Meng Rui Chang, et al. on LinkedIn:

“Read our paper in JACS (American Chemical Society)!

The Babak Lab in collaboration with Prof. Wee Han Ang, Prof. Walter Berger and City University of Hong Kong.”

Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors.

Authors: Meng Rui Chang, et al.

Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors - The Babak Lab

Maria (Masha) Babak, Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong, shared the post on LinkedIn, adding:

“I am deeply honored to be able to publish in JACS (American Chemical Society society)!

This work would not be possible without the help of my students, colleagues and mentors. Also I would like to specially thank reviewers for their extremely valuable comments that made this paper much better!

I am very happy.”

American Chemical Society cancer cell death City University of Hong Kong fight against cancer Global fight against cancer JACS Maria (Masha) Babak Meng Rui Chang Mesothelioma Tumors OncoDaily Oncology The Babak Lab Walter Berger Wee Han Ang

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care

OncoDaily Launches New Social Channel on Telegram – @OncoDaily

In Memory of Chadwick Boseman and His Colon Cancer Battle

Groundbreaking Canadian Cancer Society-funded research aims to reshape the future of advanced cancer